4/26
11:59 am
imnm
Analysts Estimate Immunome, Inc. (IMNM) to Report a Decline in Earnings: What to Look Out for [Yahoo! Finance]
Low
Report
Analysts Estimate Immunome, Inc. (IMNM) to Report a Decline in Earnings: What to Look Out for [Yahoo! Finance]
4/25
08:33 am
imnm
Immunome Appoints Sandra M. Swain to Board of Directors [Yahoo! Finance]
Low
Report
Immunome Appoints Sandra M. Swain to Board of Directors [Yahoo! Finance]
4/25
08:26 am
imnm
Immunome Appoints Sandra M. Swain to Board of Directors
Low
Report
Immunome Appoints Sandra M. Swain to Board of Directors
4/15
08:11 am
imnm
Immunome, Inc. (NASDAQ: IMNM) is now covered by analysts at Guggenheim. They set a "buy" rating and a $35.00 price target on the stock.
High
Report
Immunome, Inc. (NASDAQ: IMNM) is now covered by analysts at Guggenheim. They set a "buy" rating and a $35.00 price target on the stock.
4/12
05:12 pm
imnm
Zentalis Pharmaceuticals: Data In 1st Half Of 2024 Could Get The Ball Rolling [Seeking Alpha]
Medium
Report
Zentalis Pharmaceuticals: Data In 1st Half Of 2024 Could Get The Ball Rolling [Seeking Alpha]
4/5
08:08 am
imnm
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting [Yahoo! Finance]
Low
Report
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting [Yahoo! Finance]
4/5
08:00 am
imnm
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting
Low
Report
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting
4/1
08:08 am
imnm
Immunome, Inc. (NASDAQ: IMNM) had its price target raised by analysts at Wedbush from $27.00 to $33.00. They now have an "outperform" rating on the stock.
High
Report
Immunome, Inc. (NASDAQ: IMNM) had its price target raised by analysts at Wedbush from $27.00 to $33.00. They now have an "outperform" rating on the stock.
3/28
04:07 pm
imnm
Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets [Yahoo! Finance]
High
Report
Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets [Yahoo! Finance]
3/28
04:02 pm
imnm
Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets
High
Report
Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets
3/26
08:25 am
imnm
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala [Yahoo! Finance]
Low
Report
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala [Yahoo! Finance]
3/26
08:12 am
imnm
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome [Yahoo! Finance]
Low
Report
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome [Yahoo! Finance]
3/26
08:00 am
imnm
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
Medium
Report
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
3/26
08:00 am
imnm
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
Medium
Report
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
3/22
06:59 am
imnm
Immunome, Inc. (NASDAQ:IMNM) surges 7.6%; individual investors who own 42% shares profited along with institutions [Yahoo! Finance]
Low
Report
Immunome, Inc. (NASDAQ:IMNM) surges 7.6%; individual investors who own 42% shares profited along with institutions [Yahoo! Finance]
3/18
05:52 am
imnm
Arrayjet's ArrayPlex Platform Selected by Immunome for Use in Its Discovery of Targeted Cancer Therapies [Yahoo! Finance]
Medium
Report
Arrayjet's ArrayPlex Platform Selected by Immunome for Use in Its Discovery of Targeted Cancer Therapies [Yahoo! Finance]
3/18
05:44 am
imnm
Arrayjet’s ArrayPlex Platform Selected by Immunome for Use in Its Discovery of Targeted Cancer Therapies
Medium
Report
Arrayjet’s ArrayPlex Platform Selected by Immunome for Use in Its Discovery of Targeted Cancer Therapies
3/7
08:00 am
imnm
Immunome to Participate in the Leerink Partners Global Biopharma Conference
Medium
Report
Immunome to Participate in the Leerink Partners Global Biopharma Conference
3/1
08:00 am
imnm
Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference
Medium
Report
Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference
2/27
07:12 am
imnm
Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates [Yahoo! Finance]
Medium
Report
Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates [Yahoo! Finance]
2/20
08:25 am
imnm
Immunome Recognizes Ayala Pharmaceuticals' Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors [Yahoo! Finance]
High
Report
Immunome Recognizes Ayala Pharmaceuticals' Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors [Yahoo! Finance]
2/20
08:15 am
imnm
Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
Medium
Report
Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
2/20
08:12 am
imnm
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors [Yahoo! Finance]
Medium
Report
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors [Yahoo! Finance]
2/20
08:00 am
imnm
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
High
Report
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
2/16
04:05 pm
imnm
Immunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
High
Report
Immunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares